Floatz logo

Favezelimab

Hodgkin Disease

Merck Sharp & Dohme LLCmonoclonal_antibodyPhase 2Active
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
89/ 100

Competitive context

149 Active assets in the Hodgkin Disease cohort.

Asset / SponsorPhaseRating
CYCLOSPORIN A
City of Hope Medical Center
Phase 3BBB
FILGRASTIM
Fred Hutchinson Cancer Center
Phase 3BBB
Carboplatin
St. Petersburg State Pavlov Medical University
Phase 2BBB
Everolimus
OHSU Knight Cancer Institute
Phase 2BBB
CARMUSTINE
VIVUS LLC
Phase 2BBB

View all 50 →

Same molecule, other indications

Favezelimab is also rated in:

neoplasmDormant
B
Indicative ·
60 / 100
View asset →
colorectal cancerDormant
B
Indicative ·
60 / 100
View asset →
skin squamous cell carcinomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →